Physician profile
David C Carpenter
NPI 1760422075
$2,574.10
in general payments reported to CMS, 2019-2025
30 companies · $650 in 2025
The $650 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $140 · 2021: $378 · 2022: $351 · 2023: $411 · 2024: $352 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $503.17 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $345.63 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $288.73 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $188.09 | 2024-2025 | |
| Abbvie INC. | $144.36 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Mylan Pharmaceuticals INC. | $99.86 | 2020-2022 | |
| Baxter Healthcare | $97.62 | 2021-2025 | Perclot, Tisseel |
| Hologic Sales and Service, LLC | $87.26 | 2019-2025 | Aptima |
| Meditrina | $80.57 | 2022 | |
| Sage Therapeutics, LLC | $79.33 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $78.45 | 2019-2025 | Slynd |
| Organon LLC | $77.69 | 2022-2025 | Nexplanon, Jada System |
| Myovant Sciences INC. | $69.59 | 2021-2022 | |
| Therapeuticsmd, INC. | $65.05 | 2019-2022 | |
| Coopersurgical, INC. | $50.19 | 2023-2025 | Endosee, Paragard T 380a |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $41.45 | 2024-2025 | |
| Pfizer INC. | $41.28 | 2024 | |
| Channel Medsystems, INC. | $28.97 | 2025 | |
| Avion Pharmaceuticals | $24.84 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $22.79 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $22.07 | 2022 | |
| Boston Scientific Corporation | $19.84 | 2023 | |
| Biom'Up France Sas | $18.75 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.66 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $14.83 | 2019 | |
| Becton, Dickinson and Company | $14.73 | 2024 | Bd Max System, Bd Max Instrument |
| Ethicon US, LLC | $14.28 | 2020 | |
| Coloplast Corp | $14.22 | 2021 | |
| Merck Sharp & Dohme LLC | $13.11 | 2023 | Gardasil 9 |
| Agile Therapeutics, INC. | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Carpenter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.